On January 27, YIDU TECH (02158) announced that it repurchased 378,600 shares on the same day at a price of approximately HK$6 per share, amounting to nearly HK$2.3 million. This marks the second consecutive day of buybacks, bringing the total repurchased shares to 505,000 with a cumulative buyback value exceeding HK$3 million. In related news, Gong Rujing, the Founder and Chairperson of YIDU TECH, was recently invited to attend the 2026 Winter Davos Forum, participating in multiple high-level industry dialogues and closed-door meetings while holding intensive discussions with global leaders and partners from government, business, and academia. At the forum, Dr. Giovanni Caforio, Chairman of the Board of Novartis, announced a significant collaboration: the Novartis Foundation, the Ministry of Health of Brunei, and EVYD, a subsidiary of YIDU TECH, will jointly implement a data- and AI-driven cardiovascular disease prevention and control project—CARDIO4Cities. Concurrently, the release of an authoritative industry ranking further validates YIDU TECH's leading position in the sector. The "2025 Healthcare Big Data Enterprise Ranking" was officially unveiled, and YIDU TECH, leveraging its profound technological expertise, mature product portfolio, and extensive industry implementation experience, secured the top spot for the seventh consecutive year, continuing to lead the healthcare big data field.